Skin carcinoma in situ is an early form of skin cancer that stays in the top layer of the skin. It often shows up as a rough patch, a scaly spot, or an area that slowly changes color or texture. A routine checkup can sometimes be the first step toward diagnosis, because many people with skin carcinoma in situ do not feel pain or other symptoms at first. Skin carcinoma in situ is most often found in adults, especially older adults and people with long-term sun damage, and it can last until it is treated. It is usually not life-threatening when treated early, and common treatment includes removing the spot or using prescription creams or light-based therapy.
How many people live with Skin carcinoma in situ?
There is no single reliable estimate of how many people are living with skin carcinoma in situ worldwide or in the United States. Skin carcinoma in situ is a very early skin cancer that stays in the top layer of skin, and major cancer tracking systems such as the World Health Organization's GLOBOCAN database and the National Cancer Institute's SEER program do not usually report a separate current “people living with it” count for this condition, so experts do not have one dependable global or U.S. total.
Overview
Skin carcinoma in situSymptoms
Skin carcinoma in situ often causes a patch or spot that looks scaly, red, crusted, or slowly changing and does not heal. Early symptoms of skin carcinoma in situ can include itching, tenderness, or minor bleeding, though some people notice no symptoms.
Outlook and prognosis
Skin carcinoma in situ is highly treatable, and most people do very well after treatment. Because it stays in the top skin layer, the chance of spread is very low. Ongoing skin checks help catch any new spots early.
Causes and risk factors
Skin carcinoma in situ is usually linked to long-term ultraviolet exposure from sunlight or tanning beds. Risk rises with fair skin, older age, weakened immunity, prior skin cancers, and exposure to arsenic or radiation.
Genetic influences
Genetics usually play a smaller role in skin carcinoma in situ than long-term ultraviolet exposure. Still, inherited skin cancer risk and certain gene changes can raise susceptibility, especially in people with a strong family history or repeated lesions.
Diagnosis
Diagnosis of skin carcinoma in situ usually starts with a skin exam. A dermatologist checks the spot closely, often with a dermatoscope. A skin biopsy confirms skin carcinoma in situ.
Treatment and drugs
Skin carcinoma in situ is usually treated by removing the patch with a small procedure. Some people also have freezing treatment, cream medicine, or light-based therapy, depending on the site and type. Regular skin checks help catch any return early.
Symptoms
Skin carcinoma in situ often shows up as a skin spot that does not heal and keeps drawing your attention during everyday things like showering or getting dressed. You might notice small changes at first, such as a dry, scaly, or reddish patch that lingers for weeks or months. Many spots are painless, but some can itch, feel tender, crust over, or bleed easily.
A flat or slightly raised patch that stays in the same place is common. It may look pink, red, brown, or skin-colored and does not clear with moisturizers or routine skin care.
The area often feels dry, rough, or flaky, almost like skin that never fully heals. Some people with skin carcinoma in situ notice a crusty top layer that peels off and then returns.
The spot may itch, sting, or feel tender when clothing rubs against it. Many living with skin carcinoma in situ have little discomfort, so a painless spot can still matter.
The patch usually enlarges gradually over time rather than appearing overnight. For many, this means a spot that seems minor at first but becomes harder to ignore over weeks or months.
How people usually first notice Skin carcinoma in situ?
People usually first notice skin carcinoma in situ when a spot on the skin does not behave like a normal rash, scab, or age mark: it may stay for weeks to months, look red or pink, feel rough or scaly, or form a flat patch that slowly grows. Some people with skin carcinoma in situ also notice a sore that crusts, bleeds easily, or seems to heal and then come back, especially on sun-exposed skin such as the face, scalp, ears, neck, forearms, or hands. These early changes are often painless, which is why a new mark that persists or changes is worth having checked, because treatment is usually very effective when it is found at this stage.
Types of Skin carcinoma in situ
Skin carcinoma in situ can look quite different from one person to another, even though it stays in the top layer of the skin. Symptoms don’t always look the same for everyone. In practice, the main types of skin carcinoma in situ are usually described by how the spot looks and where it appears, especially in squamous cell carcinoma in situ.
Bowen disease
This is the classic form of squamous cell carcinoma in situ and often shows up as a slowly growing, flat red or pink patch with scale or crust. Many living with it notice a spot that looks like eczema or psoriasis but does not clear with usual skin creams.
Erythroplasia of Queyrat
This variation affects the glans or inner foreskin of the penis and usually looks smoother, brighter red, and more moist than Bowen disease on other skin. Some may find it causes tenderness, mild burning, or bleeding with friction, while others mainly notice a persistent velvety patch.
Pigmented Bowen
This less common type contains extra pigment, so it may look brown, gray, or almost black instead of pink or red. Because of that, it can resemble a mole or melanoma, but it often still has a flat surface with slight scale.
Can I slow down the onset of symptoms?
Yes, to a degree: protecting your skin from ultraviolet light is the clearest way to lower the chance that skin carcinoma in situ, a very early skin cancer, will develop or appear sooner, but it cannot guarantee prevention. Research most strongly supports avoiding tanning beds, limiting strong sun exposure, using sunscreen, shade, and protective clothing, and checking your skin for new or changing spots; these steps lower risk rather than fully prevent cancer. If you have had skin cancer before or have a higher risk, regular skin exams with a dermatologist are well-established and can catch changes early, and while these habits may help delay new spots, they cannot promise a certain outcome.
What genetics can tell you about symptoms
For skin carcinoma in situ, genetics usually does not tell doctors exactly which symptoms you will have, since many people notice the same kinds of changes, such as a rough, scaly, discolored, or slowly growing patch on the skin. What genes can sometimes help explain is risk and timing: people with certain inherited conditions that affect skin pigment or the way the body repairs sun damage can develop these changes earlier or more often than others. In most cases, though, day-to-day factors such as lifelong sun exposure, skin type, and the exact spot on the body matter more than genetics for how this condition shows up.
Causes and risk factors
Among the main risk factors for skin carcinoma in situ, long-term ultraviolet damage from the sun or tanning beds stands out. Risk is also higher with fair skin, older age, a weakened immune system, or a past skin cancer. Family history can be one part of the story, but lifestyle and environment add their own chapters. Some inherited conditions and skin that burns easily can make skin carcinoma in situ more likely. Repeated sun exposure without protection and smoking can also raise risk.
What are the most common causes or risk factors?
The biggest risk factor for skin carcinoma in situ is long-term damage from ultraviolet (UV) rays, mainly from the sun or tanning beds. It is more common in people with lighter skin that burns easily, in older adults, and in those who have had many sunburns or a previous skin cancer. Risk also goes up if the immune system is weakened, and some people inherit a higher risk because their skin has less natural protection against UV damage.
Environmental and biological risk factors
Skin carcinoma in situ is an early skin cancer that stays in the top layer of the skin. Doctors often group risks into internal (biological) and external (environmental). The main risk factors for skin carcinoma in situ are long-term ultraviolet damage, certain skin and immune traits, older age, and some past chemical, radiation, or infection-related exposures.
Repeated ultraviolet exposure from sunlight or artificial UV sources is the strongest environmental risk for skin carcinoma in situ. Damage builds up in skin cells over time, especially on areas that get regular sun such as the face, ears, scalp, neck, and hands.
People with light skin, light eyes, freckles, or skin that burns easily have less natural protection against ultraviolet damage. This makes skin carcinoma in situ more likely after the same amount of sun exposure.
Risk rises with age because skin has had more time to collect damage from ultraviolet light and other exposures. Many living with skin carcinoma in situ are older adults, although it can happen earlier.
A weakened immune system can make it harder for the body to repair abnormal skin cells or clear certain infections. Skin carcinoma in situ is more common in people after organ transplant and in others with long-term immune suppression.
Genetic risk factors
Most people with skin carcinoma in situ do not have one single inherited cause, but genes can still shape risk. The main genetic risk factors for skin carcinoma in situ include family history, inherited skin-color traits, and a small number of rare syndromes that affect DNA repair. Carrying a genetic change doesn’t guarantee the condition will appear.
Family history: Having close relatives with skin cancer can point to an inherited tendency. In many families, this risk comes from several small gene differences adding up rather than one single changed gene.
Fair skin traits: People born with very fair skin, light eyes, freckles, or skin that burns easily may inherit less natural pigment protection in the skin. These traits can raise the chance of skin carcinoma in situ, although many living with them never develop it.
Albinism: Albinism is an inherited condition that greatly reduces the amount of pigment the skin can make. With less pigment, skin cells have less built-in protection, which can increase the risk of skin carcinoma in situ.
DNA repair disorders: Rare inherited conditions that weaken DNA repair can sharply increase risk, sometimes from a young age. One example is xeroderma pigmentosum, in which skin cells have trouble fixing everyday damage.
Inherited syndromes: A few rare syndromes passed through families can make abnormal skin growth much more likely. Doctors may suspect this kind of inherited risk when skin cancers appear unusually early or several relatives are affected.
Lifestyle risk factors
Daily habits that increase ultraviolet damage are the main lifestyle factors linked to skin carcinoma in situ. In practice, the most important lifestyle risk factors for skin carcinoma in situ involve how much unprotected sun a person gets, whether they use tanning beds, and how consistently they protect their skin. Smoking may also raise risk for some forms, especially squamous cell carcinoma in situ.
Repeated unprotected sun exposure allows ultraviolet radiation to damage skin cell DNA over time. This makes abnormal cells more likely to develop and remain in the top layer of the skin as carcinoma in situ.
Indoor tanning delivers concentrated ultraviolet radiation that can trigger the same kind of DNA injury seen with natural sunlight. Regular tanning bed use can increase the chance of developing skin carcinoma in situ at a younger age.
Skipping sunscreen, protective clothing, hats, or shade increases the amount of ultraviolet damage the skin receives. Over months and years, these habits can make precancerous and in situ skin changes more likely to appear.
Frequent or severe sunburns are a sign of intense ultraviolet injury to the skin. These episodes can accelerate the cell damage that leads to carcinoma in situ, especially on regularly exposed areas.
Risk prevention
Skin carcinoma in situ is often linked to long-term sun damage, so prevention mostly centers on protecting your skin from ultraviolet light and spotting changes early. If you spend a lot of time outdoors, even routine things like walking the dog or driving can add up over the years. Prevention is about lowering risk, not eliminating it completely.
Use a broad-spectrum sunscreen with SPF 30 or higher on exposed skin, and reapply it if you stay outside. Hats, sunglasses, and tightly woven clothing add another layer of protection against the UV damage that can lead to skin carcinoma in situ.
Tanning beds expose skin to concentrated ultraviolet light that can raise the risk of skin carcinoma in situ. A tan is a sign of skin injury, not protection.
Try to limit direct sun when it is strongest, usually from late morning to midafternoon. Shade helps, but it works best when combined with sunscreen and protective clothing.
Looking at your skin regularly can help you notice rough, scaly, red, or changing patches sooner. Early symptoms of skin carcinoma in situ can be subtle, so a spot that does not heal or slowly grows should be checked by a clinician.
Can you prevent Skin carcinoma in situ?
You cannot fully prevent skin carcinoma in situ, which is a very early form of skin cancer, but you can lower the risk. The most proven steps are to protect your skin from too much sun by seeking shade, wearing protective clothing, and using sunscreen, and to avoid tanning beds. These steps help, but they cannot guarantee that skin cancer will not happen.
Transmission
Skin carcinoma in situ is not infectious, so it cannot be passed from one person to another. Touching the area, sharing towels, kissing, or being in a pool with someone who has skin carcinoma in situ will not make it spread to you.
For many, the bigger question is whether skin carcinoma in situ can run in families. It is usually linked to skin damage over time, especially from ultraviolet light, rather than direct genetic transmission of skin carcinoma in situ, although inherited traits such as fair skin can raise risk.
When to test your genes
Genetic testing is usually not part of routine care for skin carcinoma in situ. It may be worth discussing if you have many skin cancers, very early onset, a strong family history of skin cancer, or features of an inherited cancer syndrome. For most people, careful skin exams and sun protection matter far more than gene testing.
Diagnosis
Skin carcinoma in situ is often found after a spot on the skin does not heal, keeps crusting, or slowly changes in color or texture over time. For many, the first step comes when everyday activities start feeling harder, such as shaving around a sore patch or noticing a rough area that catches on clothing. The diagnosis of skin carcinoma in situ usually starts with a skin exam and is confirmed with a small tissue sample.
A doctor closely checks the size, shape, color, and surface of the area and looks for any nearby changes in the skin. They may also examine the rest of your skin because more than one suspicious spot can be present at the same time.
Your provider will ask when the spot first appeared, whether it has changed, and if it bleeds, itches, or feels tender. Past sun exposure, tanning bed use, radiation treatment, immune system problems, and previous skin cancers can help guide the diagnosis.
This is a closer look using a handheld lighted magnifier that helps show patterns not visible to the naked eye. It can help the doctor decide whether the area is more likely to be skin carcinoma in situ or another common skin condition.
A small sample of the abnormal skin is removed and sent to a lab for testing. This is the main way how skin carcinoma in situ is diagnosed, because it shows whether cancer cells are limited to the top layer of skin.
How is Skin carcinoma in situ diagnosed?
Skin carcinoma in situ, which means a very early skin cancer that has not grown deeper, is usually diagnosed after a doctor examines the spot closely and asks how long it has been there or whether it has changed. They may use a special magnifying light to look at the skin in more detail, but the diagnosis is usually confirmed with a biopsy, which means removing a small sample of the spot and checking it under a microscope. In many living with this condition, the final diagnosis depends on that lab check rather than on appearance alone.
Stages of Skin carcinoma in situ
Skin carcinoma in situ does not have defined progression stages. That is because it describes a very early skin cancer that is still limited to the top layer of the skin, rather than an illness that moves through a set step-by-step course over time. Doctors usually start with a conversation about changes such as a scaly patch, a sore that does not heal, or other early symptoms of skin carcinoma in situ, then examine the area closely. The diagnosis is usually confirmed with a skin biopsy, and follow-up checks help make sure the spot has been fully treated and that no new suspicious areas appear.
Outlook and prognosis
The outlook for skin carcinoma in situ is generally excellent because it is confined to the top layer of the skin and has not invaded deeper tissues. With timely treatment, most people are cured, and mortality from the in situ lesion itself is extremely low. The main risks are local recurrence, the development of additional skin cancers over time, and progression to invasive cancer if the lesion is left untreated. Prognosis may vary somewhat by subtype, size, location, and whether a person has immune suppression or extensive sun damage. Regular skin follow-up is important, since early detection and treatment of new or recurrent lesions helps maintain the very favorable long-term outlook.
Long-term effects
For most people, skin carcinoma in situ has an excellent outlook because it is limited to the top layer of the skin and is often cured with treatment. The main long-term concerns are the chance of it coming back in the same area, the chance of developing another skin cancer later, and lasting skin changes where it was treated. It’s important to remember that long-term doesn’t always mean progressive.
Skin carcinoma in situ can sometimes return in the same spot, especially if the abnormal cells were not fully removed or if the area is hard to treat. This means some people need repeat treatment and long-term skin checks.
Many living with skin carcinoma in situ have a higher chance of developing other skin cancers over time, particularly in sun-exposed skin. This can be more likely when there has been years of ultraviolet damage or several past lesions.
Treatment may leave a scar, a lighter or darker patch, or an area that feels firmer or thinner than nearby skin. For many, this can mean a lasting visible change on the face, scalp, arms, or legs.
The treated skin may stay more sensitive, tight, itchy, or easily irritated for a long time, although this is often mild. Some may find shaving, rubbing clothing, or sun exposure makes the area more noticeable.
How is it to live with Skin carcinoma in situ?
Living with skin carcinoma in situ often means balancing the reassuring fact that it is an early, highly treatable skin cancer with the stress of hearing the word cancer at all. Day to day, many people feel physically well, but the spot itself may be noticeable, itchy, scaly, or bothersome, and treatment can bring temporary soreness, wound care, follow-up visits, and a stronger focus on sun protection in everyday routines. For family and close friends, the main impact is usually emotional support, help with appointments or skin checks, and a shared shift toward habits that protect everyone’s skin, such as using sunscreen, seeking shade, and watching for new or changing spots.
Treatment and drugs
Skin carcinoma in situ is usually treated by removing or destroying the abnormal cells before they grow deeper into the skin. Depending on where it is, how large it is, and your overall health, treatment may include a minor procedure to cut it out, freezing, scraping with heat treatment, light-based treatment, or medicated creams placed on the skin. Some people notice it first as a rough, scaly patch that does not go away, and early treatment for skin carcinoma in situ often cures it. Your doctor may suggest the option that is most likely to clear the area while limiting scarring, and not every treatment works the same way for every person. Follow-up skin checks are important, because people with skin carcinoma in situ can develop new spots later on.
Can you cure Skin carcinoma in situ?
In many cases, yes, skin carcinoma in situ can be cured because it is an early form of skin cancer that has not grown deeper into the skin. Treatment usually removes or destroys the affected area, often with a small procedure or sometimes a medicated cream, and follow-up skin checks help catch any new spots early.
Non-drug treatment
Treatment is often focused on removing or destroying the abnormal skin area before it grows deeper. With skin carcinoma in situ, the best treatment for skin carcinoma in situ depends on where the spot is, how large it is, and whether it has come back before. Non-drug treatments often lay the foundation for care, and many can be done in a clinic with local numbing medicine rather than a hospital stay.
This removes the visible spot along with a small rim of nearby skin to lower the chance of cells being left behind. It is often used when the area is well defined or when the diagnosis needs to be confirmed under the microscope.
This is a tissue-sparing procedure that removes the skin layer by layer and checks each layer right away. It can be especially helpful on the face, ears, fingers, or genital area, where saving as much healthy skin as possible matters.
A doctor gently scrapes away the abnormal tissue and then uses heat or electricity to treat the base. This may work well for small, shallow areas, though it is not the best fit for every body site.
This treatment freezes the abnormal skin so it can peel away as the area heals. It is sometimes used for small, thin lesions, but it can cause blistering, skin color changes, or soreness for a short time.
Your genes may have an impact on how drugs work for you
For people with skin carcinoma in situ, inherited differences can sometimes affect how well the body responds to certain treatments or how easily side effects happen, including with medicated skin creams. In day-to-day care, though, treatment choices are usually based much more on where the spot is, how large it is, and how deep it goes than on genetic testing. This means many living with this condition will not need gene-based drug testing, but if treatment does not work as expected or causes unusual reactions, the care team may look more closely at why.
Pharmacological treatments
For many living with skin carcinoma in situ, medicines are mainly used when the affected area is thin and limited, or when surgery is not the best fit. The main drug treatments are topical creams that treat the spot directly, and in some cases a light-activated medicine is used in the clinic. Not everyone responds to the same medication in the same way. Your care team will choose treatment based on where the lesion is, how large it is, and whether earlier treatment has already been tried.
5-fluorouracil, often called 5-FU, is a cream that damages abnormal skin cells so they gradually peel away and are replaced by healthier skin. It is one of the most common options for topical treatment for skin carcinoma in situ, especially for small superficial areas. The treated skin often becomes red, sore, and crusted for a time before it heals.
Imiquimod is a cream that helps your own immune system attack the abnormal cells in the skin. It may be used for selected superficial lesions, especially when avoiding a procedure is important. Side effects, if they occur, can often include redness, burning, itching, and temporary skin breakdown where the cream is applied.
Aminolevulinic acid and methyl aminolevulinate are medicines placed on the skin before photodynamic therapy, a treatment that uses a special light to destroy abnormal cells. This can be helpful for some thin or surface-level areas of skin carcinoma in situ, particularly when appearance matters. Treated skin may sting, swell, and become very sensitive to light for a short period after therapy.
Genetic influences
For skin carcinoma in situ, genetics can affect risk, but they are usually only part of the picture. Many people with skin carcinoma in situ have inherited traits such as very fair skin, freckles, light-colored eyes, or skin that burns easily, which can make sun damage build up faster over time. Family history is one of the strongest clues to a genetic influence. Rare inherited conditions that make it harder for the body to repair sun-related DNA damage can raise the chance of skin carcinoma in situ, sometimes at a younger age. Still, most cases are linked more strongly to ultraviolet exposure and to gene changes that develop in skin cells during life, rather than to one single gene passed down through a family. In other words, the genetic risk for skin carcinoma in situ often acts more like a built-in tendency that interacts with sun exposure than a direct, guaranteed cause.
Is Skin carcinoma in situ genetic?
Genetics usually play a smaller role in skin carcinoma in situ than long-term ultraviolet exposure. Still, inherited skin cancer risk and certain gene changes can raise susceptibility, especially in people with a strong family history or repeated lesions.
Having a genetic risk is not necessarily a diagnosis
Genetic variants are a normal part of human biology and are found commonly across the general population. Most do not have a direct effect on health and are simply part of natural human diversity. For many genes, having a variant associated with a condition suggests a possible link rather than a definite diagnosis, especially when several genes and environmental factors are involved. In some situations, though, a single well-understood variant in a particular gene can be enough to confirm a diagnosis.
Pharmacogenetics—how genetics influence drug effects
When a cream is offered instead of a procedure, many people start asking how genetics affect treatment for skin carcinoma in situ and whether side effects can be predicted. For most people with skin carcinoma in situ, treatment is still chosen mainly by the size and location of the area and whether it can be removed or treated locally with surgery, freezing, scraping, light-based treatment, or a prescription cream. Not every difference in response is genetic, but inherited gene differences can sometimes affect how the body handles a medicine called fluorouracil (5-FU), which is sometimes used on the skin, and this may raise the chance of stronger side effects in a small number of people. Genetic changes inside the skin cells are not usually checked at this early stage, because skin carcinoma in situ is often treated right where it is and usually does not need the kind of gene-guided drug choices used for more advanced cancers. If an area is large, keeps coming back, or there is concern that it may be turning invasive, the treatment plan may need a closer review. A personal or family history of severe reactions to fluorouracil is worth mentioning, because it can sometimes help guide the safest option.
Interactions with other conditions
Skin carcinoma in situ often shows up alongside other signs of long-term sun damage, so many living with it may also have actinic keratoses or a history of other skin cancers. Doctors call it a comorbidity when two conditions occur together. This matters because a weakened immune system, such as after an organ transplant or with certain blood cancers or HIV, can make skin carcinoma in situ more likely to appear in several spots, come back after treatment, or progress if it is not treated. Day to day, this can mean a new scaly patch is harder to judge on your own, especially if you already have eczema, psoriasis, or many sun-damaged areas that make the skin look irritated. People with skin carcinoma in situ may also need closer follow-up if they have had basal cell carcinoma, squamous cell carcinoma, or melanoma before, since one skin cancer can be a marker of higher risk for others. If you are managing more than one condition, coordinated skin checks can help doctors sort out what is harmless irritation and what needs prompt treatment.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
What other conditions can cause similar symptoms to Skin carcinoma in situ?
Skin carcinoma in situ can look like common skin problems such as eczema, psoriasis, a long-lasting fungal rash, or a rough, sun-damaged patch of skin. It can also resemble a wart, a sore that does not heal, or another early skin cancer, especially basal cell skin cancer. Because these conditions can look very similar, a skin specialist may need to examine the area closely and sometimes test a small skin sample.
History
People have long noticed skin spots that changed slowly over time, especially patches that stayed scaly, reddened, or crusted and did not heal as expected. What earlier doctors saw was not always clearly separated from rashes, infections, or other growths, so many living with skin carcinoma in situ would likely have gone undiagnosed in the past. A rough patch on the arm or a stubborn plaque on the leg might have been watched for years before anyone recognized it as an early form of skin cancer.
As medical science evolved, doctors became better at linking what they could see on the skin with what showed up under the microscope. In the late 19th and early 20th centuries, detailed descriptions helped distinguish certain long-lasting, flat, scaly lesions from deeper, invasive skin cancers. This mattered because skin carcinoma in situ stays limited to the top layer of skin at first, and that difference affects treatment and outlook. Over time, early reports also made it clearer that these lesions could appear on sun-exposed skin, but in some cases could develop in other areas too.
Later, improved pathology techniques gave doctors a more precise way to confirm the diagnosis. Instead of relying only on how a spot looked, they could examine a skin sample and see that the abnormal cells had not yet broken into deeper tissue. That helped shape the modern idea of skin carcinoma in situ as a very early stage of cancer rather than a harmless rash or simply “old age” skin change.
In recent decades, awareness has grown that early symptoms of skin carcinoma in situ can be subtle. Many people first notice a patch that flakes, itches, bleeds a little after rubbing, or seems to come and go without fully disappearing. Public education about sun safety, skin checks, and biopsy of suspicious lesions has made earlier diagnosis more common. Researchers also later identified general genetic and cellular changes involved in how these skin cells become abnormal, but the biggest shift for everyday care has been practical: skin carcinoma in situ is now recognized earlier, treated more accurately, and far less likely to be dismissed as “just a dry patch.”